

**FORM PTO-1449A**

## INFORMATION DISCLOSURE CITATION

**Attorney Docket:**  
**4126-4039**

Serial No: TBA

**Applicant:**  
Sarah DONALD, Andreas GESCHER and José María JIMENO  
DOÑAOUE

Filing Date:  
Herewith

**Group Art Unit:**  
**TBA**

## U.S. PATENT / PUBLICATION DOCUMENTS

[illegible]

# FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner**

**/Chris Simmons/**

Date Considered

01/14/2008

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP §609.  
Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to Applicant.

**FORM PTO-1449B**  
**INFORMATION DISCLOSURE**  
**CITATION**

Examiner  
Initials\*

Cite No.

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

/C.S./

1.

Tabor et al., "Antioxidation Potential of Indole Compounds-Structure Activity Studies," *Biological Reactive Intermediates IV*, p. 833-836, 1990.

**/C.S./**

2.

Kesteren et al., "Yondelis® (Trabectedin, ET-743): The Development of an Anticancer Agent of Marine Origin" *Anti-Cancer Drugs*, Vol. 14, No. 7 p. 487-502, 2003.

/C.S./

3.

Donald et al., "Complete Protection By High-Dose Dexamethasone Against The Hepatotoxicity of the Novel Antitumor Drug Yondelis (ET-743) in The Rat," Cancer Research, Vol. 63, p. 5902-5908, September 2003.

/C.S./

4.

Donald et al., "Dietary Agent Indole-3-Carbinol Protects Female Rats Against the Hepatotoxicity of the Antitumor Drug ET-743 (trabectedin) Without Compromising Efficacy in a Rat Mammary Carcinoma" International Journal Of Cancer, Vol. 111, No. 6, p. 961-967, 2004.

**Examiner  
Signature**

/Chris Simmons/

Date \_\_\_\_\_

**Considered**

01/14/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

**If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.**